Is PODD a good stock to buy? We came across a bullish thesis on Insulet Corporation on The Wealth Dynasty Report’s Substack. In this article, we will summarize the bulls’ thesis on PODD. Insulet Corporation’s share was trading at $159.61 as of June 9th. PODD’s trailing and forward P/E were 37.30 and 25.71 respectively according to Yahoo Finance.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. PODD is positioned as a high-quality, long-duration compounder in diabetes technology, with the market’s overreaction to GLP-1 weight-loss drugs creating an attractive entry point despite the company’s strong underlying fundamentals.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
While sentiment has weakened since 2021 and the stock has experienced a steep drawdown, the core demand for insulin remains structurally intact, particularly among Type 1 diabetics who depend on lifelong insulin delivery, supporting durable adoption of Insulet’s Omnipod tubeless insulin pump system.
The Omnipod ecosystem functions like a recurring revenue model, with disposable pods replaced every three days, creating sticky, high-retention usage once patients are onboarded. The flagship Omnipod 5 automated insulin delivery system, integrated with CGMs such as Dexcom, continues to expand globally, enhancing patient outcomes while reinforcing switching costs. Revenue growth remains robust, with a multi-year CAGR above mid-20s, while gross margins in the mid-60% range highlight strong unit economics for a hardware-enabled subscription model.
Importantly, operating leverage is beginning to emerge as scale improves, manufacturing expansion in Malaysia enhances efficiency, and international penetration broadens the addressable market. The company’s push into Type 2 diabetes represents a major long-term upside driver, potentially expanding its market opportunity significantly beyond its current base.
Although valuation appears elevated on near-term earnings, the multiple reflects a transition toward sustainable profitability and high-quality recurring cash flows. With strong revenue visibility, expanding margins, and a large untapped patient population, Insulet Corporation offers compelling upside potential over a 5–10 year horizon, supported by structural healthcare demand and continued innovation in automated insulin delivery outlook.
Previously, we covered a bullish thesis on Medtronic plc (MDT) by Investing Intel’s Substack in May 2025, which highlighted FY2025 execution and diabetes spin-off plans. MDT’s stock price has depreciated by approximately 1.61% since our coverage. The Wealth Dynasty Report shares a similar view but emphasizes Insulet recurring Omnipod compounding and GLP-1 overreaction rather than Medtronic spin-off.
Insulet Corporation is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 55 hedge fund portfolios held PODD at the end of the first quarter which was 60 in the previous quarter. While we acknowledge the risk and potential of PODD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PODD and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
